28,796 Shares in Smith & Nephew SNATS, Inc. $SNN Acquired by Tectonic Advisors LLC

Tectonic Advisors LLC bought a new stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) in the third quarter, HoldingsChannel reports. The institutional investor bought 28,796 shares of the medical equipment provider’s stock, valued at approximately $1,045,000.

Several other hedge funds have also made changes to their positions in SNN. AlphaCore Capital LLC purchased a new position in shares of Smith & Nephew SNATS during the second quarter valued at $44,000. Banque Transatlantique SA purchased a new stake in Smith & Nephew SNATS in the first quarter worth about $52,000. Bessemer Group Inc. grew its holdings in Smith & Nephew SNATS by 111.9% during the 2nd quarter. Bessemer Group Inc. now owns 3,709 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 1,959 shares in the last quarter. Geneos Wealth Management Inc. grew its holdings in Smith & Nephew SNATS by 15.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider’s stock worth $118,000 after acquiring an additional 541 shares in the last quarter. Finally, MAI Capital Management increased its position in Smith & Nephew SNATS by 24.0% during the 2nd quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock valued at $134,000 after purchasing an additional 846 shares during the period. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Performance

NYSE SNN opened at $32.87 on Friday. Smith & Nephew SNATS, Inc. has a 52 week low of $23.69 and a 52 week high of $38.79. The company has a 50 day moving average price of $33.48 and a 200 day moving average price of $33.99. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Canaccord Genuity Group lowered their target price on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a report on Tuesday, November 11th. Sanford C. Bernstein set a $37.50 target price on Smith & Nephew SNATS and gave the company a “market perform” rating in a research report on Tuesday, October 14th. Finally, Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $35.75.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.